Mobile

A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extensio...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011000-34

A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extension phase up to a total of 60 weeks in patients with active rheumatoid arthritis despite stable treatment with methotrexate

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Efficacy of AIN457 at 16 weeks on ACR20 response.

Critère d'inclusion

  • Moderate to Severe Rheumatoid Arthritis

Liens